[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100243300":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":18,"locations":27,"responsibleParty":43,"collaborators":7,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":59,"studyType":60,"phases":7,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":29,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"University Medical Centre Ljubljana","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"BIOLOGICAL","Autologous stem cell therapy","All patients received granulocyte-colony stimulating factor (G-CSF; 5 mg\u002Fkg, 5 days). CD34+ cell were then collected by apheresis and injected transendocardially or intracororonary.",[14],{"name":15,"affiliation":16,"role":17},"Bojan Vrtovec, MD, PhD","UMC Ljubljana","PRINCIPAL_INVESTIGATOR",[19,23],{"name":15,"role":20,"phone":21,"phoneExt":7,"email":22},"CONTACT","+3861 522 1157","bojan.vrtovec@gmail.com",{"name":24,"role":20,"phone":25,"phoneExt":7,"email":26},"Gregor Poglajen, MD, PhD","+3861 522 1148","gregor.poglajen@gmail.com",[28],{"facility":16,"status":29,"city":30,"state":7,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Ljubljana","1000","Slovenia","SI",{"type":35,"coordinates":36},"Point",[37,38],14.50513,46.05108,{"lat":38,"lon":37},[41,42],{"name":15,"role":20,"phone":21,"phoneExt":7,"email":22},{"name":24,"role":20,"phone":25,"phoneExt":7,"email":26},{"type":17,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Bojan Vrtovec","Medical Director, Advanced Heart Failure and Transplantation Center","100243300","registry-of-cell-therapy-in-non-ischemic-dilated-cardiomyopathy-100243300",false,"NCT02445534","Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy","RECORD","Inclusion Criteria:\n\n* Patient inclusion criteria consisted of the following: age 18-65 years old, diagnosis of DCM according to the European Society of Cardiology position statement (9), optimal medical management for at least 6 months, left ventricular ejection fraction (LVEF) \\\u003C40%, and New York Heart Association functional Class III on stable medical therapy for at least 3 months before referral.\n\nExclusion Criteria:\n\n* Patients with acute multi-organ failure or a history of hematologic neoplasms were not included.","ALL","18 Years","65 Years",{"count":57,"type":58},250,"ESTIMATED","5 Years","OBSERVATIONAL","Although several studies have demonstrated beneficial effects of stem cell therapy in patients with non-ischemic dilated cardiomyopathy, the long term benefits and predictors of response to therapy remain undefined. The aim of this registry is to pool long-term clinical data in patients with non-ischemic dilated cardiomyopathy undergoing autologous cell therapy in an attempt to better define predictors of response to such treatment.",[63],"Cardiomyopathy, Dilated",[65],"Cell Therapy","2024-07-01",{"date":68,"type":69},"2024-07-03","ACTUAL",{"date":71,"type":7},"2005-01",{"date":73,"type":58},"2027-05",{"name":5,"class":6},1]